Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRAGE: Imaging Pulmonary Aspergillosis with Gallium-68-Deferoxamine
2023-509744-10-00Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferoxamine in pulmonary aspergillosis and allergic bronchopulmonary aspergillosis (ABPA), sponsored by Radboud University Medical Center. Primary endpoint: Quantitative uptake and target-to-background ratios of [68Ga]Ga-DFO-B. Started Apr 2024; status: completed.
02
Drugs
deferoxamine
03
Conditions
pulmonary aspergillosisallergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on 2023-509744-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509744-10-00.